The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line.
Francesco Grossi
Honoraria - Roche
Claudio Sini
No relevant relationships to disclose
Giulia Barletta
No relevant relationships to disclose
Erika Rijavec
No relevant relationships to disclose
Carlo Genova
No relevant relationships to disclose
Maria Giovanna Dal Bello
No relevant relationships to disclose
Paolo Pronzato
No relevant relationships to disclose
Paola Venturino
Employment or Leadership Position - Roche
Giovanni L. Pappagallo
No relevant relationships to disclose